Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EMN 2021 | Unravelling drug resistance and sensitization

Michel Delforge • 10 Mar 2021
EMN 2021
Multiple Myeloma Bortezomib Carfilzomib Ixazomib

Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, provides a summary of his EMN presentation, which focused on unraveling drug resistance and sensitization to proteasome inhibitors using genome-wide CRISPR-Cas9 knockout screening. This interview took place during the 2021 European Myeloma Network (EMN) congress.

Disclosures

Michel Delforge, MD, PhD, has participated in advisory boards for Amgen, Celgene-BMS, GSK, Janssen, Takeda and Sanofi; and has received research grants from Amgen, Celgene, Janssen, Takeda and Sanofi.

More from Michel Delforge

2:20
HRQoL in heavily pretreated patients with MM treated with ide-cel or standard regimens in KarMMa-3
Michel Delforge • 10 Dec 2023
2:16
Moving CAR-T therapy into the frontline setting in myeloma: insights into CARTITUDE-5 & CARTITUDE-6
Michel Delforge • 4 Oct 2023
1:50
How might inequalities in access to CAR-T therapy for multiple myeloma be addressed?
Michel Delforge • 4 Oct 2023
8:28
Treatment selection for patients with multiple myeloma at first relapse and beyond
Michel Delforge • 4 Oct 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals